acerus pharma’s natesto® to be listed for public reimbursement in quebec, building on strong 28% increase in natesto’s canadian prescriptions in q4 2017 | business wire 

$jnj $syk $celg $gsk $gild $lly $ $biib $regn $pfe $nvs $abbv $mrk $amgn $bmy $abt https://t.co/4enfi7ep6p